ストックスクリーナーアプリを入手
62.27
2.55%
1.55
プレマーケット:
62.42
0.15
+0.24%
前日終値:
$60.72
開ける：
$60.92
24時間の取引高:
2.37M
Relative Volume:
1.26
時価総額：
$7.61B
収益：
$18.47M
当期純損益:
$-589.53M
株価収益率:
-11.84
EPS:
-5.26
ネットキャッシュフロー:
$-399.80M
1週間 パフォーマンス:
-0.99%
1か月 パフォーマンス:
-1.97%
6か月 パフォーマンス:
+25.17%
1年 パフォーマンス:
+42.53%
1日の値動き範囲:
$60.01
$62.57
1週間の範囲:
$59.33
$63.00
52週間の値動き範囲:
$29.31
$70.98
Cytokinetics Inc Stock (CYTK) Company Profile
名前
Cytokinetics Inc
セクター
電話
(650) 624-3000
住所
350 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA
Compare CYTK vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CYTK
Cytokinetics Inc
|
62.27 | 7.42B | 18.47M | -589.53M | -399.80M | -5.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.89 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.50 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
749.56 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.30 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
299.02 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
Cytokinetics Inc Stock (CYTK) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-28 | 再開されました | Barclays | Overweight |
| 2025-12-18 | アップグレード | Goldman | Neutral → Buy |
| 2025-07-30 | 再開されました | Raymond James | Mkt Perform |
| 2025-04-24 | 開始されました | Barclays | Overweight |
| 2025-02-07 | 開始されました | Citigroup | Buy |
| 2025-01-22 | 開始されました | Stifel | Buy |
| 2024-11-08 | 開始されました | RBC Capital Mkts | Outperform |
| 2024-08-13 | ダウングレード | Goldman | Buy → Neutral |
| 2024-01-24 | ダウングレード | UBS | Buy → Neutral |
| 2024-01-05 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2023-11-09 | 開始されました | Goldman | Buy |
| 2023-11-07 | 開始されました | B. Riley Securities | Buy |
| 2023-08-15 | 開始されました | SVB Securities | Outperform |
| 2023-02-17 | 開始されました | BofA Securities | Neutral |
| 2022-12-23 | 繰り返されました | Needham | Buy |
| 2022-12-20 | 開始されました | Truist | Buy |
| 2022-10-11 | 開始されました | UBS | Buy |
| 2022-01-28 | 開始されました | Goldman | Buy |
| 2021-12-22 | 開始されました | Oppenheimer | Outperform |
| 2021-12-10 | 開始されました | JP Morgan | Overweight |
| 2021-10-07 | 開始されました | Jefferies | Buy |
| 2021-03-12 | 開始されました | Wolfe Research | Outperform |
| 2021-02-18 | 開始されました | Barclays | Overweight |
| 2021-01-20 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-10-29 | 開始されました | Goldman | Neutral |
| 2020-07-10 | 開始されました | Raymond James | Strong Buy |
| 2020-05-05 | 開始されました | Mizuho | Buy |
| 2020-04-09 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2018-09-21 | 開始されました | Cantor Fitzgerald | Overweight |
| 2018-09-10 | 再開されました | Morgan Stanley | Equal-Weight |
| 2017-11-22 | 繰り返されました | Morgan Stanley | Overweight |
| 2017-11-22 | ダウングレード | Needham | Strong Buy → Buy |
| 2017-11-21 | 繰り返されました | H.C. Wainwright | Buy |
| 2017-07-31 | 開始されました | Morgan Stanley | Overweight |
| 2017-03-08 | 開始されました | Rodman & Renshaw | Buy |
| 2017-02-06 | アップグレード | Needham | Buy → Strong Buy |
| 2016-12-16 | 開始されました | Cantor Fitzgerald | Overweight |
| 2016-07-28 | 繰り返されました | Needham | Buy |
| 2015-11-10 | 繰り返されました | FBR Capital | Outperform |
| 2015-11-09 | 繰り返されました | ROTH Capital | Buy |
| 2015-07-24 | 繰り返されました | MLV & Co | Buy |
| 2014-12-31 | 繰り返されました | ROTH Capital | Buy |
| 2014-11-04 | アップグレード | MLV & Co | Hold → Buy |
| 2014-04-28 | 繰り返されました | Needham | Buy |
すべてを表示
Cytokinetics Inc (CYTK) 最新ニュース
Segall Bryant & Hamill LLC Boosts Position in Cytokinetics, Incorporated $CYTK - MarketBeat
Royce & Associates LP Invests $5.50 Million in Cytokinetics, Incorporated $CYTK - MarketBeat
Legato Capital Management LLC Takes Position in Cytokinetics, Incorporated $CYTK - MarketBeat
Fisher Asset Management LLC Raises Stock Holdings in Cytokinetics, Incorporated $CYTK - MarketBeat
Cytokinetics Is Priced For A Big MYQORZO Launch - Finimize
Rafferty Asset Management LLC Has $5.72 Million Holdings in Cytokinetics, Incorporated $CYTK - MarketBeat
CYTK Should I Buy - Intellectia AI
Cytokinetics, Incorporated (NASDAQ:CYTK) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Insider Sell: B Parshall Sells 5,000 Shares of Cytokinetics Inc (CYTK) - GuruFocus
EVP at Cytokinetics (NASDAQ: CYTK) sells 886 shares after option exercise - Stock Titan
[144] CYTOKINETICS INC SEC Filing - Stock Titan
Director Lynne Parshall trims Cytokinetics (CYTK) stake in sale - Stock Titan
Cytokinetics to Participate in March Investor Conferences - The Manila Times
March investor fireside chats: Cytokinetics to webcast - Stock Titan
Cytokinetics, Incorporated (CYTK) Stock Analysis: A Biotech With A 46.52% Potential Upside - DirectorsTalk Interviews
Cytokinetics, Incorporated $CYTK Stock Position Raised by Handelsbanken Fonder AB - MarketBeat
CYTK Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Assessing Cytokinetics (CYTK) Valuation After Recent Share Price Weakness And Aficamten Expectations - Yahoo Finance
A Look At Cytokinetics (CYTK) Valuation After Recent Share Price Pullback - simplywall.st
Monashee Investment Management LLC Buys Shares of 100,000 Cytokinetics, Incorporated $CYTK - MarketBeat
Cytokinetics (HAM:KK3A) Total Receivables : €1.54 Mil (As of Sep. 2025) - GuruFocus
Cytokinetics (HAM:KK3A) Inventories, Raw Materials & Components : €0.00 Mil (As of Sep. 2025) - GuruFocus
TD Asset Management Inc Raises Stake in Cytokinetics, Incorporated $CYTK - MarketBeat
Cytokinetics (HAM:KK3A) Inventories, Inventories Adjustments : €0.00 Mil (As of Sep. 2025) - GuruFocus
Cytokinetics (HAM:KK3A) YoY Rev. per Sh. Growth : 250.00% (As of Sep. 2025) - GuruFocus
Cytokinetics (HAM:KK3A) FCF Margin % : -6,037.84% (As of Sep. 2025) - GuruFocus
Cytokinetics (HAM:KK3A) Total Equity : €-444.00 Mil (As of Sep. 2025) - GuruFocus
Cytokinetics (HAM:KK3A) Research & Development : €0.00 Mil (TTM As of Sep. 2025) - GuruFocus
HC Wainwright Estimates Cytokinetics Q3 Earnings - MarketBeat
Cytokinetics (HAM:KK3A) 1-Year ROIIC % : -84.62% (As of Sep. 2025) - GuruFocus
Cytokinetics (HAM:KK3A) Investments And Advances : €246.07 Mil (As of Sep. 2025) - GuruFocus
Cytokinetics (HAM:KK3A) COGS-to-Revenue : 51.27 (As of Sep. 2025) - GuruFocus
Cytokinetics (HAM:KK3A) Land And Improvements : €0.00 Mil (As of Sep. 2025) - GuruFocus
CYTK Technical Analysis & Stock Price Forecast - Intellectia AI
Cytokinetics (HAM:KK3A) Operating Cash Flow per Share : €-3.25 (TTM As of Sep. 2025) - GuruFocus
Decoding Cytokinetics Inc (CYTK): A Strategic SWOT Insight - GuruFocus
Cytokinetics (HAM:KK3A) Debt-to-EBITDA : -1.08 (As of Sep. 2025) - GuruFocus
Cytokinetics (HAM:KK3A) EBITDA Margin % : -14,321.10% (As of Sep. 2025) - GuruFocus
Cytokinetics (HAM:KK3A) Change In Prepaid Assets : €-7.08 Mil (TTM As of Sep. 2025) - GuruFocus
Cytokinetics (HAM:KK3A) 3-Year RORE % : 2.84% (As of Sep. 2025) - GuruFocus
Cytokinetics (CYTK) pivots to commercial growth with MYQORZO and heart failure pipeline - Stock Titan
Cytokinetics (NASDAQ:CYTK) Given New $84.00 Price Target at Leerink Partners - MarketBeat
Cytokinetics (CYTK): Leerink Partners Raises Price Target | CYTK Stock News - GuruFocus
HC Wainwright Comments on Cytokinetics Q1 Earnings - MarketBeat
Needham raises Cytokinetics stock price target to $85 on trial outlook - Investing.com South Africa
Cytokinetics, Incorporated Q4 2025 Earnings Call Summary - Yahoo Finance
Cytokinetics (CYTK) Quarterly Loss Of US$183 Million Reinforces Bearish Profitability Concerns - simplywall.st
Cytokinetics (HAM:KK3A) Current Deferred Revenue : €1.37 Mil (As of Sep. 2025) - GuruFocus
BofA raises Cytokinetics stock price target to $67 on Myqorzo - Investing.com India
Make way, Camzyos: Cytokinetics touts promising early launch for rival heart drug - Endpoints News
CYTK Posts a Wider-Than-Expected Q4 Loss, Advances Myqorzo Launch Plans - Finviz
Cytokinetics Inc (CYTK) 財務データ
収益
当期純利益
現金流量
EPS
Cytokinetics Inc (CYTK) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| PARSHALL B LYNNE | Director |
Mar 02 '26 |
Sale |
61.21 |
5,000 |
306,050 |
17,933 |
| Callos Andrew | EVP, Chief Commercial Officer |
Mar 02 '26 |
Option Exercise |
37.63 |
886 |
33,340 |
51,326 |
| Callos Andrew | EVP, Chief Commercial Officer |
Mar 02 '26 |
Sale |
61.62 |
886 |
54,595 |
50,440 |
| Callos Andrew | EVP, Chief Commercial Officer |
Feb 05 '26 |
Option Exercise |
23.26 |
15,000 |
348,900 |
65,440 |
| Callos Andrew | EVP, Chief Commercial Officer |
Feb 05 '26 |
Sale |
61.93 |
15,000 |
928,950 |
50,440 |
| Callos Andrew | EVP, Chief Commercial Officer |
Feb 02 '26 |
Option Exercise |
37.63 |
886 |
33,340 |
51,326 |
| Callos Andrew | EVP, Chief Commercial Officer |
Feb 02 '26 |
Sale |
62.10 |
886 |
55,021 |
50,440 |
| Callos Andrew | EVP, Chief Commercial Officer |
Jan 05 '26 |
Option Exercise |
23.26 |
15,000 |
348,900 |
65,440 |
| Callos Andrew | EVP, Chief Commercial Officer |
Jan 05 '26 |
Sale |
60.28 |
15,000 |
904,200 |
50,440 |
| Callos Andrew | EVP, Chief Commercial Officer |
Jan 02 '26 |
Option Exercise |
37.63 |
885 |
33,303 |
51,325 |
0.11%
6.00%
大文字化:
|
ボリューム (24 時間):